Results from a phase 1a/1b study of botensilimab (BOT), a novel innate/adaptive immune activator, plus balstilimab (BAL; anti-PD-1 antibody) in metastatic heavily pretreated microsatellite stable colorectal cancer (MSS CRC).-MedSci.cn

Results from a phase 1a/1b study of botensilimab (BOT), a novel innate/adaptive immune activator, plus balstilimab (BAL; anti-PD-1 antibody) in metastatic heavily pretreated microsatellite stable colorectal cancer (MSS CRC).

El-Khoueiry, AB; Fakih, M; Gordon, MS; Tsimberidou, AM; Bullock, AJ; Wilky, BA; Trent, JC; Margolin, KA; Mahadevan, D; Balmanoukian, AS; Sanborn, RE; Schwartz, GK; Bockorny, B; Moser, JC; Grossman, JE; Feliu, WIO; Rosenthal, K; O'Day, S; Lenz, HJ; Schlechter, BL

内科

外科

专科科室

热点

按科室浏览

临床工具

科研工具

其他工具

科研数智化

真实世界研究解决方案

数字化学术传播解决方案

其它

Results from a phase 1a/1b study of botensilimab (BOT), a novel innate/adaptive immune activator, plus balstilimab (BAL; anti-PD-1 antibody) in metastatic heavily pretreated microsatellite stable colorectal cancer (MSS CRC).

科室

工具

服务